Regeneron Pharmaceuticals (REGN) Other Accumulated Expenses (2010 - 2020)

Regeneron Pharmaceuticals' Other Accumulated Expenses history runs 10 years deep, the most recent figure standing at $122.4 million for Q4 2020.

• In Q4 2020, Other Accumulated Expenses rose 44.0% year-over-year to $122.4 million; the TTM figure through Dec 2020 stood at $122.4 million (up 44.0% YoY), while the FY2020 annual figure was $122.4 million, up 44.0% from the prior year.
• Other Accumulated Expenses was $122.4 million for Q4 2020 at Regeneron Pharmaceuticals, up from $96.9 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $122.4 million in Q4 2020 to a low of $267000.0 in Q4 2017.
• Historically, Other Accumulated Expenses has averaged $39.8 million across 4 years, with a median of $3.7 million in 2016.
• The sharpest annual moves came in 2016 and 2017: Other Accumulated Expenses surged 518.22% in 2016, then sank 93.51% in 2017.
• A 4-year view of Other Accumulated Expenses shows it stood at $1.2 million in 2016, then tumbled by 77.33% to $267000.0 in 2017, then surged by 31735.21% to $85.0 million in 2019, then surged by 44.0% to $122.4 million in 2020.
• The last three Other Accumulated Expenses figures came in at $122.4 million (Q4 2020), $96.9 million (Q3 2020), and $103.8 million (Q2 2020), per Business Quant data.